Aarti Drugs will hold a meeting of the Board of Directors of the Company on 3 May 2024.Powered by Capital Market - Live News

Aarti Drugs announced that the United States Food and Drug Administration (US FDA) has inspected the Formulations (Oncology) manufacturing facility of its Subsidiary (Pinnacle Life Science) at Baddi, Himachal Pradesh from 16 to 22 of April 2024.On conclusion of the inspection, the company has received 5 inspectionalobservations in Form 483, where none of the observations are related to Data Integrity. The company will work closely with US FDA in resolving all points. Powered by Capital Market - Live News

Aarti Drugs announced that the Board of Directors of the Company at its meeting held on 24 January 2024, inter alia, have recommended the interim dividend of Rs 1 per equity Share (i.e. 10%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Net profit of Aarti Drugs declined 0.03% to Rs 36.67 crore in the quarter ended December 2023 as against Rs 36.68 crore during the previous quarter ended December 2022. Sales declined 8.74% to Rs 605.94 crore in the quarter ended December 2023 as against Rs 663.96 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales605.94663.96 -9 OPM %11.5810.64 - PBDT64.2162.30 3 PBT51.5549.68 4 NP36.6736.68 0 Powered by Capital Market - Live News

Net profit of Aarti Drugs declined 13.87% to Rs 31.62 crore in the quarter ended December 2023 as against Rs 36.71 crore during the previous quarter ended December 2022. Sales declined 13.96% to Rs 538.21 crore in the quarter ended December 2023 as against Rs 625.53 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales538.21625.53 -14 OPM %11.1011.03 - PBDT54.6760.83 -10 PBT42.8748.96 -12 NP31.6236.71 -14 Powered by Capital Market - Live News